XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Net revenue        
Product sales $ 1,145 $ 32 $ 1,430 $ 711
Costs and expenses        
Cost of revenue 952 209 1,281 903
Research and development 1,397 2,633 2,959 6,050
Selling, general and administrative 7,358 9,029 23,021 14,823
Loss from operations (8,562) (11,839) (25,831) (21,065)
Interest expense 248 794 1,105 877
Change in fair value of earnout liability (5,174) (29,938)
Change in fair value of PIPE make-whole liability (3,336) (432)
Change in fair value of private warrants 420 480
Change in fair value of SAFEs 508 10 558
Merger-related transaction costs expensed 4,009
Other non-operating losses, net 1,049 1,049
Loss before income taxes (1,769) (13,141) (2,114) (22,500)
Provision (benefit) for income taxes (16) 1 (1,296) 32
Net loss and comprehensive loss (1,753) (13,142) (818) (22,532)
Deemed dividend from warrant price adjustment 661 661
Net loss available to common stockholders $ (2,414) $ (13,142) $ (1,479) $ (22,532)
Net loss per common share:        
Basic (in Dollars per share) $ (0.09) $ (0.94) $ (0.06) $ (1.71)
Diluted (in Dollars per share) $ (0.21) $ (0.94) $ (0.1) $ (1.71)
Weighted-average common shares outstanding:        
Basic (in Shares) 28,045,995 14,025,304 24,259,035 13,189,879
Diluted (in Shares) 29,199,253 14,025,304 24,914,569 13,189,879